Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Cyclic peptides
Reexamination Certificate
2000-02-22
2001-10-30
Davenport, Avis M. (Department: 1653)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Cyclic peptides
C514S009100, C514S011400, C424S185100, C435S242000, C206S569000
Reexamination Certificate
active
06310177
ABSTRACT:
TECHNICAL FIELD
The present invention relates generally to methods for regulating occludin-mediated processes, and more particularly to the use of modulating agents comprising an occludin cell adhesion recognition sequence and/or an antibody that specifically recognizes such a sequence for inhibiting functions such as cell adhesion and the formation of tissue permeability barriers.
BACKGROUND OF THE INVENTION
Cell adhesion is a complex process that is important for maintaining tissue integrity and generating physical and permeability barriers within the body. All tissues are divided into discrete compartments, each of which is composed of a specific cell type that adheres to similar cell types. Such adhesion triggers the formation of intercellular junctions (i.e., readily definable contact sites on the surfaces of adjacent cells that are adhering to one another), also known as tight junctions, gap junctions, spot desmosomes and belt desmosomes. The formation of such junctions gives rise to physical and permeability barriers that restrict the free passage of cells and other biological substances from one tissue compartment to another. For example, the blood vessels of all tissues are composed of endothelial cells. In order for components in the blood to enter a given tissue compartment, they must first pass from the lumen of a blood vessel through the barrier formed by the endothelial cells of that vessel. Similarly, in order for substances to enter the body via the gut, the substances must first pass through a barrier formed by the epithelial cells of that tissue. To enter the blood via the skin, both epithelial and endothelial cell layers must be crossed.
Cell adhesion is mediated by specific cell surface adhesion molecules (CAMs). There are many different families of CAMs, including the immunoglobulin, integrin, selectin and cadherin superfamilies, and each cell type expresses a unique combination of these molecules. Cadherins are a rapidly expanding family of calcium-dependent CAMs (Munro et al., In:
Cell Adhesion and Invasion in Cancer Metastasis
, P. Brodt, ed., pp. 17-34, RG Landes Co.(Austin Tex., 1996). The cadherins (abbreviated CADs) are membrane glycoproteins that generally promote cell adhesion through homophilic interactions (a CAD on the surface of one cell binds to an identical CAD on the surface of another cell). Cadherins have been shown to regulate epithelial, endothelial, neural and cancer cell adhesion, with different CADs expressed on different cell types. For example, N (neural)—cadherin is predominantly expressed by neural cells, endothelial cells and a variety of cancer cell types. E (epithelial)—cadherin is predominantly expressed by epithelial cells. VE (vascular endothelial)—cadherin is predominantly expressed by endothelial cells. Other CADs are P (placental)—cadherin, which is found in human skin, and R (retinal)—cadherin. A detailed discussion of the cadherins is provided in Munro S B et al., 1996, In:
Cell Adhesion and Invasion in Cancer Metastasis
, P. Brodt, ed., pp.17-34 (RG Landes Company, Austin Tex.) and Lampugnani and Dejana,
Curr. Opin. Cell Biol.
9:674-682, 1997.
CAD-mediated cell adhesion triggers a cascade of events that lead to the formation of intercellular junctions, and ultimately to the establishment of permeability barriers between tissue compartments. The intercellular junction that is directly responsible for the creation of permeability barriers that prevent the diffusion of solutes through paracellular spaces is known as the tight junction, or zonula occludens (Anderson and van Itallie,
Am. J. Physiol.
269:G467-G475, 1995; Lampugnani and Dejana,
Curr. Opin. Cell Biol.
9:674-682, 1997).
The only transmembrane component of tight junctions that has been described thus far is occludin (Furuse et al.,
J. Cell Biol.
123:1777-1788, 1993; Furuse et al.,
J. Cell Sci.
109:429-435, 1996). This protein appears to be expressed by all endothelial cell types, as well as by most epithelial cell types. Occludin is an integral membrane protein (
FIG. 1
) that is composed of two extracellular domains (EC1 and EC2), four hydrophobic domains (TM1-TM4) that transverse the plasma membrane, and three cytoplasmic domains (CP1-CP3). The structures of all known mammalian occludins are similar (
FIG. 2
; Ando-Akatsuka et al.,
J. Biol. Chem.
133:43-47, 1996). Occludin is believed to be directly involved in cell adhesion and the formation of tight junctions (Furuse et al.,
J. Cell Sci.
109:429-435, 1996; Chen et al.,
J. Cell Biol.
138:891-899, 1997). It has been proposed that occludin promotes cell adhesion through homophilic interactions (an occludin on the surface of one cell binds to an identical occludin on the surface of another cell). A detailed discussion of occludin structure and function is provided by Lampugnani and Dejana,
Curr. Opin. Cell Biol.
9:674-682, 1997.
Although cell adhesion is required for certain normal physiological functions, there are situations in which the level of cell adhesion is undesirable. For example, many pathologies (such as autoimmune diseases and inflammatory diseases) involve abnormal cellular adhesion. Cell adhesion may also play a role in graft rejection. In such circumstances, modulation of cell adhesion may be desirable.
In addition, permeability barriers arising from cell adhesion create difficulties for the delivery of drugs to specific tissues and tumors within the body. For example, skin patches are a convenient tool for administering drugs through the skin. However, the use of skin patches has been limited to small, hydrophobic molecules because of the epithelial and endothelial cell barriers. Similarly, endothelial cells render the blood capillaries largely impermeable to drugs, and the blood/brain barrier has hampered the targeting of drugs to the central nervous system. In addition, many solid tumors develop internal barriers that limit the delivery of anti-tumor drugs and antibodies to inner cells.
Attempts to facilitate the passage of drugs across such barriers generally rely on specific receptors or carrier proteins that transport molecules across barriers in vivo. However, such methods are often inefficient, due to low endogenous transport rates or to the poor functioning of a carrier protein with drugs. While improved efficiency has been achieved using a variety of chemical agents that disrupt cell adhesion, such agents are typically associated with undesirable side-effects, may require invasive procedures for administration and may result in irreversible effects.
Accordingly, there is a need in the art for compounds that modulate cell adhesion and improve drug delivery across permeability barriers without such disadvantages. The present invention fulfills this need and further provides other related advantages.
SUMMARY OF THE INVENTION
The present invention provides compounds and methods for modulating occludin-mediated cell adhesion and the formation of permeability barriers.
Within one aspect, cyclic peptides are provided, wherein the cyclic peptides comprise the sequence LYHY (SEQ ID NO:1) and modulate occludin-mediated cell adhesion. Certain cyclic peptides have the formula:
wherein X
1
, and X
2
are optional, and if present, are independently selected from the group consisting of amino acid residues and combinations thereof in which the residues are linked by peptide bonds, and wherein X
1
and X
2
independently range in size from 0 to 10 residues, such that the sum of residues contained within X
1
and X
2
ranges from 1 to 12;
wherein Y
1
and Y
2
are independently selected from the group consisting of amino acid residues, and wherein a covalent bond is formed between residues Y
1
and Y
2
; and
wherein Z
1
and Z
2
are optional, and if present, are independently selected from the group consisting of amino acid residues and combinations thereof in which the residues are linked by peptide bonds. Such cyclic peptides may comprise modifications such as an N-acetyl or N-alkoxybenzyl group and/or a C-terminal amide or ester group. Cyclic peptides may be cyclized via, for
Blaschuk Orest W.
Gour Barbara J.
Symonds James Matthew
Adherex Technologies Inc.
Davenport Avis M.
Seed Intellectual Property Law Group PLLC
LandOfFree
Compounds and methods for modulating tissue permeability does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for modulating tissue permeability, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for modulating tissue permeability will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2553848